News Archive 2007
ASHBURN, Va., December 18, 2007 /PRNewswire/ -- Innocoll, Inc., a privately-held specialty pharmaceutical company, announced that the first of three planned phase 2 clinical trials sponsored by its wholly owned subsidiary, Innocoll Technologies Ltd, to investigate CollaRx® GENTAMICIN TOPICAL for the treatment and prevention of infected diabetic foot ulcers, has commenced dosing.
ASHBURN, Va., December 17, 2007 / PRNewswire / - Innocoll, Inc., a privately held specialty pharmaceutical company, announced that it has closed an equity financing investment to raise $30 million through the sale of convertible preferred stock in a private placement with three institutional investors led by Camulos Capital LP together with NewSmith Asset Management LLP and Morgan Stanley & Co, Incorporated. The existing principal shareholders, Rolf and William Schmidt, also converted existing loans totalling approximately $16 million into convertible preferred stock. The financing will be used to fund a series of phase 2 and phase 3 clinical trials for Innocoll's lead product development programs, payment of financing fees, and general corporate purposes.
ASHBURN, Va., November 28, 2007 / PRNewswire / - Innocoll, Inc. announced that its wholly-owned subsidiary, Syntacoll AG, has been notified that pursuant to Rule 51(4) EPC, the European Patent Office (EPO) intends to grant two of Innocoll's patent applications which are both based on its proprietary CollaRx technology; Patent No. 1259269 entitled "Agent for the Treatment of Wounds" and Patent No. 1265648 entitled "Novel Natural Polymer-Based Material with Improved Properties for Use in Human and Veterinary Medicine and the Method of Manufacture such".
ASHBURN, Va., October 17, 2007 /PRNewswire/ - Innocoll, Inc. announced that its wholly-owned subsidiary, Innocoll Technologies Ltd., has filed an Investigational New Drug (IND) application for its CollaRx® BUPIVACAINE TOPICAL, which is under development for the treatment of painful chronic skin ulcers and burns. The product is a biodegradable and fully resorbable Bupivacaine Collagen Sponge formulated using Innocoll's proprietary CollaRx technology, which is already under phase 2 clinical development for the management of post-operative surgical wound pain.
ASHBURN, Va., September 26, 2007 /PRNewswire/ - Innocoll, Inc., a privately-held specialty pharmaceutical company, announced the following status and progress updates regarding its clinical development programs and specialty pharmaceutical operations:
ASHBURN, Va., September 12, 2007 /PRNewswire/ --Innocoll, Inc. announced that its wholly-owned subsidiary, Innocoll Technologies Ltd., has entered into a strategic collaboration with TGR BioSciences Pty Ltd to evaluate the combination of Innocoll's collagen-based drug delivery technology, CollaRx®, with TGR Biosciences' proprietary wound healing compound, TGR-265.
CHARLOTTE, NC and ASHBURN, VA--Sep 10, 2007 -- Innocoll, Inc. and Bourne Partners today announced the formation of CollMED Laboratories, Inc. ("CollMED") to commercialize and develop four products in the U.S. advanced wound care segment. The company's first product, CollaGUARDTM, was approved by the FDA in late 2006 and is based on Innocoll's proprietary CollaRx® membrane technology. The launch of CollaGUARDTM is targeted to take place in the fourth quarter of 2007.
ASHBURN, Va.,September 6 , 2007 /PRNewswire/ -- Innocoll, Inc. announced that it has agreed the sale of its CollaRx® GENTAMICIN SURGICAL IMPLANT and European sales and marketing infrastructure to EUSA Pharma Inc., a transatlantic specialty pharmaceutical company focused on oncology, pain control and critical care.
ASHBURN, Va., August 8, 2007 /PRNewswire/ –– Innocoll, Inc. announced its wholly-owned subsidiary, Innocoll Pharmaceuticals Ltd., has received a class IV medical device licence for its CollaRx® GENTAMICIN SURGICAL IMPLANT from the Canadian regulatory authority, Health Canada.
ASHBURN, Va.,June 6, 2007 /PRNewswire/ –– Innocoll, Inc., a privately-held specialty pharmaceutical company, announced that its wholly owned subsidiary, Innocoll Technologies Ltd, has filed an Investigational New Drug (IND) application for its CollaRx® GENTAMICIN SURGICAL IMPLANT, which is under development for the prevention of surgical site infections as an adjunct to standard infection prophylaxis. Following the positive outcome to a pre-IND meeting with the FDA held earlier this year, Innocoll is proposing to conduct two multi-centered phase 3 clinical trials in theUS to support a future New Drug Application (NDA) submission.